<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">100966035</journal-id>
<journal-id journal-id-type="pubmed-jr-id">22040</journal-id>
<journal-id journal-id-type="nlm-ta">Trends Mol Med</journal-id>
<journal-id journal-id-type="iso-abbrev">Trends Mol Med</journal-id>
<journal-title-group>
<journal-title>Trends in molecular medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1471-4914</issn>
<issn pub-type="epub">1471-499X</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28461154</article-id>
<article-id pub-id-type="pmc">5504908</article-id>
<article-id pub-id-type="doi">10.1016/j.molmed.2017.04.002</article-id>
<article-id pub-id-type="manuscript">NIHMS873632</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Pathophysiology of TFII-I: Old Guard Wearing New Hats</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Roy</surname>
<given-names>Ananda L</given-names>
</name>
<xref ref-type="aff" rid="A1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>*</label>Laboratory of Molecular Biology and Immunology, Biomedical Research Center, National Institutes of Health/National Institute on Aging, 251 Bayview Blvd, Baltimore, MD 21224</aff>
<author-notes>
<corresp id="FN1">Phone: 301-435-8056, <email>ananda.roy@nih.gov</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>18</day>
<month>5</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>28</day>
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>6</month>
<year>2018</year>
</pub-date>
<volume>23</volume>
<issue>6</issue>
<fpage>501</fpage>
<lpage>511</lpage>
<!--elocation-id from pubmed: 10.1016/j.molmed.2017.04.002-->
<abstract>
<p id="P2">The biochemical properties of the signal-induced multifunctional transcription factor TFII-I indicate that it is involved in a variety of gene regulatory processes. Although gene ablation in murine models and cell based assays show that it is encoded by an essential gene, <italic>GTF2I/Gtf2i,</italic> its physiologic role in human disorders was relatively unknown until recently. Novel studies show it is involved in an array of human diseases including neurocognitive disorders, Systemic Lupus Erythymatosus, and cancer. Here, I bring together these diverse observations to illustrate its multiple patho-physiological functions and further conjecture on how these could be related to its known biochemical properties. I expect that a better understanding of these “structure-function” relationships would lead to future diagnostic and/or therapeutic potentials.</p>
</abstract>
<kwd-group>
<kwd>TFII-I</kwd>
<kwd>GTF2I</kwd>
<kwd>transcription</kwd>
<kwd>lymphoma</kwd>
<kwd>SLE</kwd>
<kwd>WBS</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>